Valuation: Vaxcyte, Inc.

Capitalization 7.56B 6.51B 5.95B 5.68B 10.41B 726B 10.58B 71.41B 27.63B 345B 28.39B 27.78B 1,200B P/E ratio 2026 *
-6.15x
P/E ratio 2027 * -7.65x
Enterprise value 7.5B 6.46B 5.9B 5.63B 10.33B 720B 10.5B 70.84B 27.41B 342B 28.16B 27.56B 1,191B EV / Sales 2026 *
-
EV / Sales 2027 * 81.9x
Free-Float
99.47%
Yield 2026 *
-
Yield 2027 * -
1 day-2.13%
1 week-1.17%
Current month-8.47%
1 month-13.33%
3 months-3.16%
6 months+7.60%
Current year+13.55%
1 week 52.24
Extreme 52.24
54.74
1 month 48.49
Extreme 48.49
63.31
Current year 43.94
Extreme 43.945
65
1 year 29.08
Extreme 29.08
65
3 years 27.66
Extreme 27.66
121.06
5 years 16.78
Extreme 16.78
121.06
10 years 15.51
Extreme 15.51
121.06
Manager TitleAgeSince
Corporate Officer/Principal 62 2013-05-26
Chief Executive Officer 58 2013-10-31
Director of Finance/CFO 56 2020-04-30
Director TitleAgeSince
Director/Board Member 58 2013-10-31
Director/Board Member 59 2021-09-15
Director/Board Member 58 2018-04-30
Change 5d. change 1-year change 3-years change Capi.($)
-2.13%-1.17%+69.55%+4.03% 7.56B
-0.14%+3.34%+42.69%+84.71% 50.1B
+0.12%-3.44%+67.99%+49.40% 45.82B
-5.60%+7.69%+62.36%+466.37% 23.66B
-2.65%-4.86%-3.02%-17.01% 22.65B
+3.19%+3.12%+41.22%-27.18% 17.8B
-1.66%+2.59%+30.04%-41.59% 16.08B
-2.91%-10.30%+47.85%+186.19% 14.14B
-7.00%-6.69%-26.94%+821.86% 13.09B
+0.41%-2.37%+40.93% - 13B
Average -1.84%-2.12%+37.27%+169.64% 22.39B
Weighted average by Cap. -1.37%-1.30%+41.36%+139.53%

Financials

2026 *2027 *
Net sales - 87.15M 74.99M 68.56M 65.42M 120M 8.36B 122M 823M 318M 3.97B 327M 320M 13.83B
Net income -1.23B -1.06B -966M -921M -1.69B -118B -1.72B -11.58B -4.48B -55.9B -4.61B -4.51B -195B -1.05B -901M -824M -786M -1.44B -100B -1.47B -9.89B -3.83B -47.7B -3.93B -3.85B -166B
Net Debt -60.19M -51.8M -47.36M -45.18M -82.83M -5.77B -84.2M -568M -220M -2.74B -226M -221M -9.55B -424M -365M -333M -318M -583M -40.66B -593M -4B -1.55B -19.3B -1.59B -1.56B -67.24B
Logo Vaxcyte, Inc.
Vaxcyte, Inc. is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. The Company's pipeline includes VAX-31, VAX-24 and VAX-XL. VAX-31, a 31-valent PCV candidate being evaluated in the OPUS Phase III adult clinical program and in a Phase II infant clinical program, is being developed for the prevention of IPD and is the broadest-spectrum PCV candidate in the clinic today. VAX-24, a 24-valent PCV candidate, is designed to cover more serotypes than any infant PCV on-market. VAX-XL leverages the Company’s carrier-sparing, site-specific conjugation technology. It is re-engineering the way highly complex vaccines are made through XpressCF, its cell-free protein synthesis platform exclusively licensed from Sutro Biopharma, Inc. Its pipeline also includes VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections, and VAX-GI, a vaccine candidate designed to prevent Shigella.
Employees
507
Date Price Change Volume
26-05-15 52.39 $ -2.13% 1,294,465
26-05-14 53.53 $ -1.33% 1,363,672
26-05-13 54.25 $ +0.41% 1,423,838
26-05-12 54.03 $ +0.07% 1,260,710
26-05-11 53.99 $ +1.85% 1,514,859
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
52.39USD
Average target price
109.00USD
Spread / Average Target
+108.05%

Quarterly revenue - Rate of surprise